Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 141 of the 141 references it cites were found in a registry or an index.
Abstract
Table 1dProperties of currently available glucose-lowering agents that may guide treatment choice in individual patients with type 2 diabetes mellitus Class Compound(s) Cellular mechanism
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Antihyperglycemic therapy in type 2 diabetes: general recommendations. Moving from the top to the bottom of the figure, potential sequences of antihyperglycemic therapy. In most patients, begin with lifestyle changes; metformin monotherapy is added at, or soon after, diagnosis (unless there are explicit contraindications). If the HbA1c target is not achieved after ∼3 months, consider one of the five treatment options combined with metformin: a sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, or basal insulin. (The order in the chart is determined by historical introduction and route of administration and is not meant to denote any specific preference.) Choice is based on patient and drug characteristics, with the over-riding goal of improving glycemic control while minimizing side effects. Shared decision making with the patient may help in the selection of therapeutic options. The figure displays drugs commonly used both in the U.S. and/or Europe. Rapid-acting secretagogues (meglitinides) may be used in place of sulfonylureas. Other drugs not shown (α-glucosidase inhibitors, colesevelam, dopamine agonists, pramlintide) may be used where available in selected patients but have modest efficacy and/or limiting side effects. In patients intolerant of, or with contraindications for, metformin, select initial drug from other classes depicted and proceed accordingly. In this circumstance, while published trials are generally lacking, it is reasonable to consider three-drug combinations other than metformin. Insulin is likely to be more effective than most other agents as a third-line therapy, especially when HbA1c is very high (e.g., ≥9.0%). The therapeutic regimen should include some basal insulin before moving to more complex insulin strategies (Fig. 3). Dashed arrow line on the left-hand side of the figure denotes the option of a more rapid progression from a two-drug combination directly to multiple daily insulin doses, in those patients with severe hyperglycemia (e.g., HbA1c ≥10.0–12.0%). DPP-4-i, DPP-4 inhibitor; Fx's, bone fractures; GI, gastrointestinal; GLP-1-RA, GLP-1 receptor agonist; HF, heart failure; SU, sulfonylurea. aConsider beginning at this stage in patients with very high HbA1c (e.g., ≥9%). bConsider rapid-acting, nonsulfonylurea secretagogues (meglitinides) in patients with irregular meal schedules or who develop late postprandial hypoglycemia on sulfonylureas. cSee Table 1 for additional potential adverse effects and risks, under “Disadvantages.” dUsually a basal insulin (NPH, glargine, detemir) in combination with noninsulin agents. eCertain noninsulin agents may be continued with insulin (see text). Refer to Fig. 3 for details on regimens. Consider beginning at this stage if patient presents with severe hyperglycemia (≥16.7–19.4 mmol/L [≥300–350 mg/dL]; HbA1c ≥10.0–12.0%) with or without catabolic features (weight loss, ketosis, etc.).](https://figures.cochat.ai/paper-figures/128f54a8a50241f9bf5b53c4e153f5da/management-of-hyperglycemia-in-type-2-diabetes-a-patient-centered-approach-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Prolonged follow up showed that in some instances the benefit is retained for 10 years or more153–155”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [154]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For patients with type 2 diabetes, the risk of hypoglycemia depends on the medications used (96).”
From Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society (2013) · cites this paper as [96]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For patients with type 2 diabetes, sulfonylureas are the oral agents that pose the greatest risk for iatrogenic hypoglycemia and substitution with other classes of oral agents or even glucagon-like peptide 1 analogs should be considered in the event of troublesome hypoglycemia (96).”
From Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society (2013) · cites this paper as [96]
The cited source says what the claim attributes to it.
In the citing paper
“For patients with type 2 diabetes, sulfonylureas are the oral agents that pose the greatest risk for iatrogenic hypoglycemia and substitution with other classes of oral agents or even glucagon-like peptide 1 analogs should be considered in the event of troublesome hypoglycemia (96).”
From Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society (2013) · cites this paper as [96]
The cited source says what the claim attributes to it.
In the citing paper
“For patients with type 2 diabetes, the risk of hypoglycemia depends on the medications used (96).”
From Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society (2013) · cites this paper as [96]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 1×
“Relationship of glycemic control to outcomes It is well established that the risk of microvascular and macrovascular complications is related to glycemia, as measured by HbA1c; this remains a major focus of therapy (29).”
BackgroundThe metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Self-citationIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationGlycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis
Buchwald, H., Estok, R., Fahrbach, K., Banel, D., Jensen, M. D., Pories, W. J., Bantle, J. P., & Sledge, I. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.041 · Cited by 2,551
Kahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166
Park, Y.-W., Zhu, S., Palaniappan, L., Heshka, S., Carnethon, M. R., & Heymsfield, S. B. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.4.427 · Cited by 2,074
Boulé, N. G., Haddad, E., Kenny, G. P., Wells, G. A., & Sigal, R. J. (2001) · JAMA · doi:10.1001/jama.286.10.1218 · Cited by 1,889
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Bantle (2008) · doi:10.2337/dc08-s061 · Cited by 1,795
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M., & for The STOP-NIDDM Trial Research Group (2003) · JAMA · doi:10.1001/jama.290.4.486 · Cited by 1,624
Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2011) · Annals of Medicine · doi:10.3109/07853890.2010.518623 · Cited by 1,293
Booth, G., & Cheng, A. Y. Y. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.010 · Cited by 1,220
Intensive glucose control and macrovascular outcomes in type 2 diabetes
Turnbull, F. M., Abraira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W. C., Evans, G. W., Gerstein, H. C., Holman, R. R., Moritz, T. E., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1470-0 · Cited by 1,189
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Oral Antidiabetic Agents: Current Role in Type 2 Diabetes Mellitus
Krentz, A. J., & Bailey, C. J. (2005) · Drugs · doi:10.2165/00003495-200565030-00005 · Cited by 1,108
Global guideline for type 2 diabetes
(2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.10.001 · Cited by 1,064
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
Thomas, N., K, S., & Kapoor, N. (2016) · A Practical Guide to Diabetes Mellitus · doi:10.5005/jp/books/12651_7 · Cited by 943
Rodbard, H. W., Jellinger, P. S., Davidson, J. A., Einhorn, D., Garber, A. J., Grunberger, G., Handelsman, Y., Horton, E. S., Lebovitz, H., Levy, P., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.6.540 · Cited by 942
Bonds, D. E., Miller, M. E., Bergenstal, R. M., Buse, J. B., Byington, R. P., Cutler, J. A., Dudl, R. J., Ismail-Beigi, F., Kimel, A. R., Hoogwerf, B., et al. (2010) · BMJ · doi:10.1136/bmj.b4909 · Cited by 933 · cited 1×
“It remains unknown whether hypoglycemia was the cause of the increased mortality in the intensive group (130,131).”
BackgroundSelf-citationSkyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., et al. (2009) · Diabetes Care · doi:10.2337/dc08-9026 · Cited by 881
Self-citationZinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
Self-citationA self-regulation program for maintenance of weight loss
Wing, R. R., Tate, D. F., Gorin, A. A., Raynor, H. A., & Fava, J. L. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061883 · Cited by 830
Bolen, S., Feldman, L., Vassy, J., Wilson, L., Yeh, H.-C., Marinopoulos, S., Wiley, C., Selvin, E., Wilson, R., Bass, E. B., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-6-200709180-00178 · Cited by 823
Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
Cryer, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0822-9 · Cited by 794
Booth, G. L., Kapral, M. K., Fung, K., & Tu, J. V. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68967-8 · Cited by 783
Guyatt, G. H., Haynes, R. B., Jaeschke, R. Z., Cook, D. J., Green, L., Naylor, C. D., Wilson, M. C., Richardson, W. S., & for the Evidence-Based Medicine Working Group (2000) · JAMA · doi:10.1001/jama.284.10.1290 · Cited by 748
We need minimally disruptive medicine
May, C., Montori, V. M., & Mair, F. S. (2009) · BMJ · doi:10.1136/bmj.b2803 · Cited by 734
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712
Self-citationLago, R. M., Singh, P. P., & Nesto, R. W. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61514-1 · Cited by 710
Three-year efficacy of complex insulin regimens in type 2 diabetes
Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., & Paul, S. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905479 · Cited by 667
The Pathology of Atherosclerosis: Plaque Development and Plaque Responses to Medical Treatment
Insull, W. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.10.013 · Cited by 639
Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L. (2011) · Diabetes Care · doi:10.2337/dc10-1068 · Cited by 625
Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00336 · Cited by 609
Elmer, P. J., Obarzanek, E., Vollmer, W. M., Simons-Morton, D., Stevens, V. J., Young, D. R., Lin, P.-H., Champagne, C., Harsha, D. W., Svetkey, L. P., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-7-200604040-00007 · Cited by 596
Nissen, S. E., & Wolski, K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.207 · Cited by 594
UK prospective diabetes study (UKPDS): VIII. Study design, progress and performance
UK Prospective Diabetes Study Group (1991) · Diabetologia · doi:10.1007/bf00400195 · Cited by 543
Ferrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1133 · Cited by 540
Self-citationKlein, S., Sheard, N. F., Pi-Sunyer, X., Daly, A., Wylie-Rosett, J., Kulkarni, K., & Clark, N. G. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.2067 · Cited by 540
Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review
Deacon, C. F. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01306.x · Cited by 525
Epidemiology and Natural History of NAFLD and NASH
Ong, J. P., & Younossi, Z. M. (2007) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.02.009 · Cited by 457
Importance of Weight Management in Type 2 Diabetes: Review with Meta-analysis of Clinical Studies
Anderson, J. W., Kendall, C. W. C., & Jenkins, D. J. A. (2003) · Journal of the American College of Nutrition · doi:10.1080/07315724.2003.10719316 · Cited by 448
Rosenstock, J., Davies, M., Home, P. D., Larsen, J., Koenen, C., & Schernthaner, G. (2008) · Diabetologia · doi:10.1007/s00125-007-0911-x · Cited by 447
Karagiannis, T., Paschos, P., Paletas, K., Matthews, D. R., & Tsapas, A. (2012) · BMJ · doi:10.1136/bmj.e1369 · Cited by 435
Self-citationUse of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency
Lipska, K. J., Bailey, C. J., & Inzucchi, S. E. (2011) · Diabetes Care · doi:10.2337/dc10-2361 · Cited by 432
Self-citationIndividualizing Glycemic Targets in Type 2 Diabetes Mellitus: Implications of Recent Clinical Trials
Ismail-Beigi, F., Moghissi, E., Tiktin, M., Hirsch, I. B., Inzucchi, S. E., & Genuth, S. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-8-201104190-00007 · Cited by 386
Self-citationLamanna, C., Monami, M., Marchionni, N., & Mannucci, E. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01349.x · Cited by 364
Nyenwe, E. A., Jerkins, T. W., Umpierrez, G. E., & Kitabchi, A. E. (2011) · Metabolism · doi:10.1016/j.metabol.2010.09.010 · Cited by 343
Glycemic Control, Complications, and Death in Older Diabetic Patients
Huang, E. S., Liu, J. Y., Moffet, H. H., John, P. M., & Karter, A. J. (2011) · Diabetes Care · doi:10.2337/dc10-2377 · Cited by 343
Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes
Davies, M., Storms, F., Shutler, S., Bianchi-Biscay, M., Gomis, R., & for the AT.LANTUS Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.6.1282 · Cited by 314 · cited 1×
“For example, the addition of 1–2 units (or, in those already on higher doses, increments of 5–10%) to the daily dose once or twice weekly if the fasting glucose levels are above the preagreed target is a reasonable approach (89).”
BackgroundEfficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
Vilsbøll, T., Rosenstock, J., Yki‐Järvinen, H., Cefalu, W. T., Chen, Y., Luo, E., Musser, B., Andryuk, P. J., Ling, Y., Kaufman, K. D., et al. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01173.x · Cited by 305 · cited 1×
“Data concerning the glycemic benefits of incretin-based therapy combined with basal insulin are accumulating; combination with GLP-1 receptor agonists may be helpful in some patients (97,98).”
BackgroundBantle, J. P., Wylie-Rosett, J., Albright, A. L., Apovian, C. M., Clark, N. G., Franz, M. J., Hoogwerf, B. J., Lichtenstein, A. H., Mayer-Davis, E., Mooradian, A. D., et al. (2008) · University Libraries (University of Maryland) · doi:10.13016/f2uw-dtxz · Cited by 297
Nauck, M. A. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.002 · Cited by 295
Self-citationThe Diabetes Mellitus Medication Choice Decision Aid: A Randomized Trial
Mullan, R. J., Montori, V. M., Shah, N. D., Christianson, T. J. H., Bryant, S. C., Guyatt, G. H., Perestelo-Perez, L. I., Stroebel, R. J., Yawn, B. P., Yapuncich, V., et al. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.293 · Cited by 283
Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes
DeFronzo, R. A. (2011) · Diabetes Care · doi:10.2337/dc11-0064 · Cited by 257
Patient-Important Outcomes in Registered Diabetes Trials
Gandhi, G. Y. (2008) · JAMA · doi:10.1001/jama.299.21.2543 · Cited by 252
Loke, Y. K., Kwok, C. S., & Singh, S. (2011) · BMJ · doi:10.1136/bmj.d1309 · Cited by 245
Triple Therapy in Type 2 Diabetes
Rosenstock, J., Sugimoto, D., Strange, P., Stewart, J. A., Soltes-Rak, E., Dailey, G., & on behalf of the Insulin Glargine 4014 Study Investigators (2006) · Diabetes Care · doi:10.2337/diacare.29.03.06.dc05-0695 · Cited by 235
Avilés-Santa, L., Sinding, J., & Raskin, P. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-3-199908030-00004 · Cited by 225
Effectiveness of Lifestyle Interventions for Individuals With Severe Obesity and Type 2 Diabetes
Unick, J. L., Beavers, D., Jakicic, J. M., Kitabchi, A. E., Knowler, W. C., Wadden, T. A., Wing, R. R., & for the Look AHEAD Research Group (2011) · Diabetes Care · doi:10.2337/dc11-0874 · Cited by 218
Gaziano, J. M., Cincotta, A. H., O'Connor, C. M., Ezrokhi, M., Rutty, D., Ma, Z. J., & Scranton, R. E. (2010) · Diabetes Care · doi:10.2337/dc09-2009 · Cited by 213
UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance.
(1991) · PubMed · Cited by 191
New Drugs for the Treatment of Diabetes: Part II: Incretin-Based Therapy and Beyond
Inzucchi, S. E., & McGuire, D. K. (2008) · Circulation · doi:10.1161/circulationaha.107.735795 · Cited by 187
Self-citationAdjust to Target in Type 2 Diabetes
Bergenstal, R. M., Johnson, M., Powers, M. A., Wynne, A., Vlajnic, A., Hollander, P., & Rendell, M. (2008) · Diabetes Care · doi:10.2337/dc07-2137 · Cited by 181
Self-citationThe Stunned β Cell: A Brief History
Ferrannini, E. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.04.009 · Cited by 175
Self-citationGreenfield, S., Billimek, J., Pellegrini, F., Franciosi, M., De Berardis, G., Nicolucci, A., & Kaplan, S. H. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-12-200912150-00005 · Cited by 170
Unraveling the Science of Incretin Biology
Nauck, M. A. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.012 · Cited by 168
Self-citationContraindications can damage your health—is metformin a case in point?
Holstein, A., & Stumvoll, M. (2005) · Diabetologia · doi:10.1007/s00125-005-0026-1 · Cited by 165
Overview of Newer Agents: Where Treatment Is Going
DeFronzo, R. A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.008 · Cited by 158
The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence
Nordin, C. (2010) · Diabetologia · doi:10.1007/s00125-010-1752-6 · Cited by 157
Gross, J. L., Kramer, C. K., Leitão, C. B., Hawkins, N., Viana, L. V., Schaan, B. D., Pinto, L. C., Rodrigues, T. C., Azevedo, M. J., & for the Diabetes and Endocrinology Meta-analysis Group (DEMA)* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-10-201105170-00007 · Cited by 150
Chen, K.-W., Boyko, E. J., Bergstrom, R. W., Leonetti, D. L., Newell-Morris, L., Wahl, P. W., & Fujimoto, W. Y. (1995) · Diabetes Care · doi:10.2337/diacare.18.6.747 · Cited by 144
Initiate Insulin by Aggressive Titration and Education (INITIATE)
Yki-Järvinen, H., Juurinen, L., Alvarsson, M., Bystedt, T., Caldwell, I., Davies, M., Lahdenperä, S., Nijpels, G., & Vähätalo, M. (2007) · Diabetes Care · doi:10.2337/dc06-1357 · Cited by 139
Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?
Tahrani, A. A., Varughese, G. I., Scarpello, J. H., & Hanna, F. W. F. (2007) · BMJ · doi:10.1136/bmj.39255.669444.ae · Cited by 138
The Relationship Between Glycemic Control and Falls in Older Adults
Nelson, J. M., Dufraux, K., & Cook, P. F. (2007) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2007.01430.x · Cited by 133
Insulin Secretagogues, Sulfonylurea Receptors and KATP Channels
Bryan, J., Crane, A., Vila-Carriles, W., Babenko, A., & Aguilar-Bryan, L. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612054546879 · Cited by 133
Diabetes Medications Related to an Increased Risk of Falls and Fall-Related Morbidity in the Elderly
Berlie, H. D., & Garwood, C. L. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m551 · Cited by 131
Colesevelam lowers glucose and lipid levels in type 2 diabetes: The clinical evidence
Fonseca, V. A., Handelsman, Y., & Staels, B. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01181.x · Cited by 130
Incretin mimetics as a novel therapeutic option for hepatic steatosis
Tushuizen, M. E., Bunck, M. C., Pouwels, P. J., Van Waesberghe, J. H. T., Diamant, M., & Heine, R. J. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01315.x · Cited by 129
Self-citationKoro, C. E., Lee, B. H., & Bowlin, S. J. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.10.020 · Cited by 126
Davis, T. M. E., Wright, A. D., Mehta, Z., Cull, C. A., STRATTON, I. M., Bottazzo, G. F., Bosi, E., Mackay, I. R., & Holman, R. R. (2005) · Diabetologia · doi:10.1007/s00125-005-1690-x · Cited by 125
Where Is the Patient in Diabetes Performance Measures?
Glasgow, R. E., Peeples, M., & Skovlund, S. E. (2008) · Diabetes Care · doi:10.2337/dc07-1845 · Cited by 125
Incretin-Based Therapies: Review of Current Clinical Trial Data
Peters, A. L. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.007 · Cited by 119
Self-citationGerich, J., Raskin, P., Jean-Louis, L., Purkayastha, D., & Baron, M. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2093 · Cited by 116
Van de Laar, F. A., Lucassen, P. L., Akkermans, R. P., Van de Lisdonk, E. H., & De Grauw, W. J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005061.pub2 · Cited by 115
Management of type 2 diabetes: summary of updated NICE guidance
Home, P., Mant, J., Diaz, J., & Turner, C. (2008) · BMJ · doi:10.1136/bmj.39560.442095.ad · Cited by 108
Davidson, M. B., Raskin, P., Tanenberg, R. J., Vlajnic, A., & Hollander, P. (2011) · Endocrine Practice · doi:10.4158/ep10323.or · Cited by 107
Sluik, D., Boeing, H., Montonen, J., Pischon, T., Kaaks, R., Teucher, B., Tjonneland, A., Halkjaer, J., Berentzen, T. L., Overvad, K., et al. (2011) · American Journal of Epidemiology · doi:10.1093/aje/kwr048 · Cited by 102
Smith, R. J., Nathan, D. M., Arslanian, S. A., Groop, L., Rizza, R. A., & Rotter, J. I. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1966 · Cited by 100
Owens, D. R., Luzio, S. D., Sert‐Langeron, C., & Riddle, M. C. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01459.x · Cited by 99
Diabetes Mellitus and Heart Failure: Epidemiology, Mechanisms, and Pharmacotherapy
Masoudi, F. A., & Inzucchi, S. E. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.013 · Cited by 97
Self-citationSchernthaner, G., Barnett, A. H., Betteridge, D. J., Carmena, R., Ceriello, A., Charbonnel, B., Hanefeld, M., Lehmann, R., Malecki, M. T., Nesto, R., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1702-3 · Cited by 97
Metformin: The Safest Hypoglycaemic Agent in Chronic Kidney Disease?
Nye, H. J., & Herrington, W. G. (2011) · Nephron Clinical Practice · doi:10.1159/000323739 · Cited by 92
Ilag, L. L., Kerr, L., Malone, J. K., & Tan, M. H. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.003 · Cited by 88
Acarbose: oral antidiabetes drug with additional cardiovascular benefits
Hanefeld, M., & Schaper, F. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.2.153 · Cited by 87
Current treatment of non‐alcoholic fatty liver disease
Ahmed, M. H., & Byrne, C. D. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00926.x · Cited by 84
Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus
Singh‐Franco, D., Robles, G. I., & Gazze, D. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.04.005 · Cited by 84
Blonde, L. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.005 · Cited by 81
Riveline, J., Danchin, N., Ledru, F., Varroud-Vial, M., & Charpentier, G. (2003) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70030-7 · Cited by 76
Type 2 Diabetes: Assessing the Relative Risks and Benefits of Glucose-lowering Medications
Bergenstal, R. M., Bailey, C. J., & Kendall, D. M. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.07.017 · Cited by 76
Self-citationMurad, M. H., Shah, N. D., Houten, H. K. V., Ziegenfuss, J. Y., Deming, J. R., Beebe, T. J., Smith, S. A., Guyatt, G. H., & Montori, V. M. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.08.005 · Cited by 74
Goals of Glycemic Control in Frail Older Patients With Diabetes
Lee, S. J. (2011) · JAMA · doi:10.1001/jama.2011.404 · Cited by 70
Roberts, V. L., Stewart, J. A., Issa, M., Lake, B., & Melis, R. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.10.017 · Cited by 68
Treatment of Patients Over 64 Years of Age With Type 2 Diabetes
Del Prato, S., Heine, R. J., Keilson, L., Guitard, C., Shen, S. G., & Emmons, R. P. (2003) · Diabetes Care · doi:10.2337/diacare.26.7.2075 · Cited by 64
Akalin, S., Berntorp, K., Ceriello, A., Das, A. K., Kilpatrick, E. S., Koblik, T., Munichoodappa, C. S., Pan, C. Y., Rosenthall, W., Shestakova, M., et al. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02165.x · Cited by 60
N of 1 trials in diabetes: making individual therapeutic decisions
Τσάπας, Α., & Matthews, D. R. (2008) · Diabetologia · doi:10.1007/s00125-008-0983-2 · Cited by 53
Self-citationGordon, N. F., Salmon, R. D., Franklin, B. A., Sperling, L. S., Hall, L. K., Leighton, R. F., & Haskell, W. L. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.08.039 · Cited by 53
Lee, K. S. S., Appleton, C. P., Lester, S. J., Adam, T. J., Hurst, R. T., Moreno, C. A., & Altemose, G. T. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.07.073 · Cited by 52
7 Insulin action and substrate competition
Groop, L., & Ferrannini, E. (1993) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(05)80243-5 · Cited by 51
Self-citationReview article: Thiazolidinediones and heart failure
Chaggar, P. S., Shaw, S. M., & Williams, S. G. (2009) · Diabetes and Vascular Disease Research · doi:10.1177/1479164109338772 · Cited by 50
Translating Comparative Effectiveness Into Practice: The Case of Diabetes Medications
Shah, N. D., Mullan, R. J., Breslin, M., Yawn, B. P., Ting, H. H., & Montori, V. M. (2010) · Medical Care · doi:10.1097/mlr.0b013e3181d5956c · Cited by 48
Matthews, D. R., & Τσάπας, Α. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.036 · Cited by 47
Self-citationDavidson, J. A. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0469 · Cited by 46
Jabbour, S. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01757.x · Cited by 44
Intensified glucose control in type 2 diabetes—whose agenda?
Yudkin, J. S., Richter, B., & Gale, E. A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61112-9 · Cited by 43
Strowig, S. M., & Raskin, P. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00440.x · Cited by 42
Raccah, D. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00846.x · Cited by 40
Counterpoint: Intensive Glucose Control and Mortality in ACCORD—Still Looking for Clues
Riddle, M. C. (2010) · Diabetes Care · doi:10.2337/dc10-1658 · Cited by 38
Monogenic diabetes: implications for therapy of rare types of disease
Malecki, M. T., & Mlynarski, W. M. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00736.x · Cited by 32
The Treat-to-Target Trial and Related Studies
Riddle, M. C. (2006) · Endocrine Practice · doi:10.4158/ep.12.s1.71 · Cited by 30
Bell, D. S. H., Dharmalingam, M., Kumar, S., & Sawakhande, R. B. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01408.x · Cited by 28
Sulistio, M. S., Carothers, C., Mangat, M., Lujan, M., OLIVEROS, R. A., & CHILTON, R. J. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0015-9 · Cited by 26
International Diabetes Center Treatment of Type 2 Diabetes Glucose Algorithm
Simonson, G., Cuddihy, R. M., Reader, D., & Bergenstal, R. M. (2011) · Diabetes Management · doi:10.2217/dmt.10.22 · Cited by 21
Self-citationConsensus guidelines, algorithms and care of the individual patient with type 2 diabetes
Nolan, J. J. (2010) · Diabetologia · doi:10.1007/s00125-010-1767-z · Cited by 20
Individualizing treatment targets in diabetes care
Buse, J. B. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.230 · Cited by 18
Self-citationThe importance of titrating starting insulin regimens in patients with type 2 diabetes
Garber, A. J. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01138.x · Cited by 17
Severe iatrogenic hypoglycemia in type 2 diabetes mellitus
Cryer, P. E. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0355 · Cited by 16
The combinatorics of medications precludes evidence-based algorithms for therapy
Rodbard, D. (2010) · Diabetologia · doi:10.1007/s00125-010-1904-8 · Cited by 8
Research works printed but not linked: 3
- Berard, 2008, Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada, Canadian Journal of Diabetes, 32, S1
- NICE, 2009, Type 2 Diabetes: The Management of Type 2 Diabetes: NICE Clinical Guideline 87
- Committee on Quality of Health Care in America, 2001, Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century
Cited by
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Self-citationDeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Self-citation
Metadata
- Authors
- Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R.
- Affiliations
- Yale New Haven Hospital (US)
- Park Nicollet Clinic (US)
- University of North Carolina at Chapel Hill (US)
- Diabetes Center/Department of Internal Medicine, VU University Medical Center, Amsterdam, the Netherlands; the
- University of Pisa (IT)
- Diabeteszentrum Bad Lauterberg (DE)
- University of Southern California (US)
- Second Medical Department, Aristotle University Thessaloniki, Thessaloniki, Greece; the
- Thomas Jefferson University (US)
- Churchill Hospital (GB)
- Corresponding author
- Inzucchi, Silvio E.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-05-11
- Volume
- 35
- Issue
- 6
- Pages
- 1364-1379
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3357214
- OpenAlex
- W2172193326
- Cited by
- 3,207
- References
- 141
- Citations by year
- 2026: 18 · 2025: 54 · 2024: 72 · 2023: 95 · 2022: 95 · 2021: 119 · 2020: 132 · 2019: 147 · 2018: 218 · 2017: 274 · 2016: 349 · 2015: 477 · 2014: 588 · 2013: 441 · 2012: 124
- FWCI
- 415.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Yale University
- University of Southern California
- University of Miami
- Wayne State University
- Georgetown University
- Case Western Reserve University
- School of Medicine, Case Western Reserve University
- MedStar Health Research Institute
- National Institute for Health and Care Research (NF-SI-0508-10272)
- University of Sydney
- University of Melbourne
- University of Toronto
- European Association for the Study of Diabetes
- Université de Nantes
- University of Ioannina
- University of Illinois at Urbana-Champaign
- School of Medicine, University of Kansas
- Health Science Center, University of Tennessee
- Leonard M. Miller School of Medicine
- Leonard M. Miller School of Medicine, University of Miami
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- hyperglycemia management, type 2 diabetes, glucose-lowering agents, patient-centered care, treatment selection
- MeSH terms
- Age Factors, Algorithms, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Europe, Female, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemic Agents, Kidney Diseases, Liver Diseases, Male, Risk Factors, United States, Patient-Centered Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.